Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125

被引：0
|
作者：
Nekulova, M
Pecen, L
Kalabova, R
Simickova, M
Topolcan, O
Pikner, R
Vondracek, V
Valik, D
机构：
[1] Masaryk Mem Canc Inst, Dept Lab Med, Brno 65665, Czech Republic
[2] Masaryk Mem Canc Inst, Dept Gynecol, Brno 65665, Czech Republic
[3] Charles Univ, Dept Nucl Med, Plzen 30599, Czech Republic
来源：
CLINICAL CHEMISTRY | 2002年 / 48卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
下载
收藏
页码：1364 / 1367
页数：4
相关论文
共 50 条
  • [1] Predicting response of ovarian cancer to paclitaxel treatment: Mathematical modelling based on trend analysis of CA125, TPS and thymidine kinase.
    Nekulova, M
    Pecen, L
    Kalabova, R
    Simickova, M
    Vondracek, V
    Valik, D
    CLINICAL CHEMISTRY, 2001, 47 (06) : A126 - A127
  • [2] Clinical (WHO) and serum tumor marker (CA125) response to platinum based chemotherapy after treatment with paclitaxel in patients with ovarian cancer (OVCA)
    Vermorken, JB
    Huijskes, RVHP
    Hoekman, K
    Burger, CW
    Verheijen, RHM
    Heitbrink, MA
    Pinedo, HM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 517 - 517
  • [3] EARLY SERUM CA125 RESPONSE AND OUTCOME IN EPITHELIAL OVARIAN-CANCER
    REDMAN, CWE
    BLACKLEDGE, GR
    KELLY, K
    POWELL, J
    BUXTON, EJ
    LUESLEY, DM
    EUROPEAN JOURNAL OF CANCER, 1990, 26 (05) : 593 - 596
  • [4] CA125 in ovarian cancer
    Scholler, Nathalie
    Urban, Nicole
    BIOMARKERS IN MEDICINE, 2007, 1 (04) : 513 - 523
  • [5] Serum CA125 level before the development of ovarian cancer
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 (02) : 95 - 99
  • [6] SERUM CA125 LEVEL BEFORE THE DEVELOPMENT OF OVARIAN CANCER
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2008, 30 (03): : 91 - 96
  • [7] THE USE OF EARLY SERUM CA125 RESPONSE IN THE MANAGEMENT OF EPITHELIAL OVARIAN-CANCER
    REDMAN, CWE
    BLACKLEDGE, G
    BUXTON, EJ
    LUESLEY, DM
    CHAN, KK
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 452 - 452
  • [8] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Serum CA125 to define response
    Rustin, GJS
    Nelstrop, A
    McClean, P
    OVARIAN CANCER 4, 1996, : 129 - 134
  • [10] Targeting CA125 transcription for ovarian cancer treatment.
    Yue, Er
    Yang, Guangchao
    Yao, Yuanfei
    Wang, Guangyu
    Zhang, Yanqiao
    Wang, Edward W.
    CANCER RESEARCH, 2021, 81 (13)
12345